Chlorproguanil-dapsone versus sulfadoxine-pyrimethamine for sequential episodes of uncomplicated falciparum malaria in Kenya and Malawi: A randomised clinical trial

Lancet

Volumn 360, Issue 9340, 2002, Pages 1136-1143

  Sulo, J ^a   Chimpeni, P ^b   Hatcher, J ^c   Kublin, J G ^d   Plowe, C V ^d   Molyneux, M E ^b,e   Marsh, K ^a,f   Taylor, T E ^g   Watkins, W M ^h   Winstanley, P A ^h  

^a KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^b MALAWI LIVERPOOL WELLCOME TRUST CLINICAL RESEARCH PROGRAMME   (Malawi)

^c Alberta Cancer Board   (Canada)

^d University of Maryland School of Medicine Center for Vaccine Development   (United States)

^e LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g MICHIGAN STATE UNIVERSITY   (United States)

^h UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROGUANIL PLUS DAPSONE; DAPSONE DERIVATIVE; FANSIDAR; HALOFANTRINE; HEMOGLOBIN; UNCLASSIFIED DRUG;

ANEMIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DISEASE SEVERITY; DRUG EFFECT; DRUG ELIMINATION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; INFANT; KENYA; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALAWI; MALE; PARASITEMIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT FAILURE; TREATMENT OUTCOME; VOMITING;

EID: 0037068963     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)11198-6     Document Type: Article

References (25)

1. Snow R.W., Craig M.H., Deichmann U., Marsh K. Estimating mortality, morbidity and disability due to malaria among Africa's non-pregnant population. Bull World Health Organ. 77:1999;624-640.
2. Goodman C.A., Coleman P.G., Mills A.J. Cost-effectiveness of malaria control in sub-Saharan Africa. Lancet. 354:1999;378-384.
3. Winstanley P.A. Chemotherapy for falciparum malaria: the armoury, the problems and the prospects. Parasitology Today. 16:2000;146-153.
4. Trape J.F. The public health impact of chloroquine resistance in Africa. Am J Trop Med Hyg. 64:(suppl 1-2):2001;12-17.
5. Watkins W.M., Mosobo M. Treatment of Plasmodium falciparum malaria with pyrimethamine-sulfadoxine: selective pressure for resistance is a function of long elimination half-life. Trans R Soc Trop Med Hyg. 87:1993;75-78.
6. Watkins W.M., Mberu E.K., Winstanley P.A., Plowe C. The efficacy of antifolate combinations in Africa: a predictive model based on pharmacodynamic and pharmacokinetic analyses. Parasitol Today. 13:1997;459-464.
7. Nzila A., Nduati E., Mberu E., et al. Molecular evidence of greater selective pressure for drug resistance exerted by the long acting antifolate pyrimethamine/sulfadoxine compared with the shorter acting chlorproguanil-dapsone on Kenyan Plasmodium falciparum. J Infect Dis. 181:2000;2023-2028.
8. Snewin V.A., England S.M., Sims P.F., Hyde J.E. Characterisation of the dihydrofolate reductase-thymidylate synthetase gene from human malaria parasites highly resistant to pyrimethamine. Gene. 76:1989;41-52.
9. Foote S.J., Galatis D., Cowman A.F. Amino acids in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum involved in cycloguanil resistance differ from those involved in pyrimethamine resistance. Proc Natl Acad Sci USA. 87:1990;3014-3017.
10. Plowe C.V., Cortese J.F., Djimde A., et al. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. J Infect Dis. 176:1997;1590-1596.
11. Nzila-Mounda A., Mberu E.K., Sibley C.H., Plowe C.V., Winstanley P.A., Watkins W.M. Kenyan Plasmodium falciparum field isolates: correlation between pyrimethamine and chlorcycloguanil activity in vitro and point mutations in the dihydrofolate reductase gene. Antimicrob Agents Chemother. 42:1998;164-169.
12. Brooks D.R., Wang P., Read M., Watkins W.M., Sims P.F., Hyde J.E. Sequence variation of the hydroxymethyldihydropterin pyrophosphokinase dihydropteroate synthetase gene in lines of the human malaria parasite Plasmodium falciparum, with differing resistance to sulfadoxine. Eur J Biochem. 224:1994;397-405.
13. Hastings MD, Bates SJ, Blackstone EA, Monks SM, Mutabingwa TK, Sibley CH. Highly pyrimethamine-resistant alleles of dihydrofolate reductase in isolates of Plasmodium falciparum from Tanzania. Trans R Soc Trop Med Hyg (in press).
14. Winstanley P.A., Watkins W.M., Muhia D., Szwandt S., Amukoye E., Marsh K. Chlorproguanil-dapsone for uncomplicated falciparum malaria in young children: pharmacokinetics and therapeutic range. Trans R Soc Trop Med Hyg. 91:1997;322-327.
15. Amukoye E., Winstanley P.A., Watkins W.M., et al. Chlorproguanil-dapsone: an effective treatment for uncomplicated falciparum malaria. Antimicrob Agents Chemother. 41:1997;2261-2264.
16. Winstanley P.A., Mberu E.K., Szwandt I.S.F., Breckenridge A.M., Watkins W.M. The in-vitro activity of novel antifolate drug combinations against Plasmodium falciparum and human granulocyte colony-forming-units. Antimicrob Agents Chemother. 39:1995;948-952.
17. Mutabingwa T., Nzila A., Mberu E., et al. Chlorproguanil-dapsone for treatment of drug-resistant falciparum malaria in Tanzania. Lancet. 358:2001;1218-1223.
18. Kublin J.G., Dzinjalamala F., Kamwendo D., et al. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis. 185:2001;380-388.
19. Nevill C.G., Some E.S., Mung'ala V.O., et al. Insecticide-treated bednets reduce mortality and severe morbidity from malaria among children on the Kenyan coast. Trop Med Int Health. 1:1996;139-146.
20. World Health Organisation. Severe falciparum malaria, Trans R Soc Trop Med Hyg, 2000; 94 (suppl 1).
21. World Health Organisation. Assessment of therapeutic efficacy of antimalarial drugs: WHO/MAL/96.1077. Geneva: WHO, 1996.
22. Nosten F., ter Kuile F.O., Luxemburger C., et al. Cardiac effects of antimalarial treatment with halofantrine. Lancet. 341:1993;1054-1056.
23. Byrd S.R., Gelber R.H. Effect of dapsone on haemoglobin concentration in patients with leprosy. Lepr Rev. 62:1991;171-178.
24. Mookherjee S., Howard V., Nzila-Mouanda A., Watkins W., Sibley C.H. Identification and analysis of dihydrofolate reductase alleles from Plasmodium falciparum present at low frequency in polyclonal patient samples. Am J Trop Med Hyg. 61:1999;131-140.
25. Brockman A., Price R.N., van Vugt M., et al. Plasmodium falciparum antimalarial drug susceptibility on the north-western border of Thailand during five years of extensive use of artesunate-mefloquine. Trans R Soc Trop Med Hyg. 94:2000;537-544.